LICOGLIFLOZIN
Licogliflozin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | 4 | — | — | — | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 4 | — | — | — | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 4 | — | — | — | 4 |
| Overweight | D050177 | — | E66.3 | — | 3 | — | — | — | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | — | — | — | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 2 | — | — | — | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
| Diarrhea | D003967 | — | R19.7 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LICOGLIFLOZIN |
| INN | licogliflozin |
| Description | Licogliflozin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1. |
| Classification | Small molecule |
| Drug class | phlorozin derivatives, phenolic glycosides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2 |
Identifiers
| PDB | — |
| CAS-ID | 1291094-73-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297625 |
| ChEBI ID | — |
| PubChem CID | 52913524 |
| DrugBank | — |
| UNII ID | 57J06X6EI0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC5A2
SLC5A2
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 244 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use